Positive phase 3 dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in rad 2021 late-breaking session

Positive phase 3 dupixent® (dupilumab) d ata in c hildren 6 m onths to 5 y ears with m oderate-to-severe a topic d ermatitis f eatured in rad 2021 l ate-breaking s ession

REGN Ratings Summary

REGN Quant Ranking